SCHEMBL6877133

SCHEMBL6877133

CN(C)CCOC(=O)c1cnc(OCCN(C)C)nc1Oc1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 1/20 0.41
CYP1A2 P05177 3/20 0.41
POLB P06746 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
LTA4H P09960 1/20 0.38
ESR1 P03372 2/20 0.38
CACNA1H O95180 2/20 0.38
CACNA1B Q00975 1/20 0.38
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6878766 0.89 KDM4E (0.46) ALDH1A1KDM4ESMN1; SMN2LTA4HESR1
Dimethylaminoethanol SCHEMBL6877129 0.85 KDM4E (0.43) ALDH1A1KDM4ESMN1; SMN2LTA4HESR1
SCHEMBL6881043 0.83 POLB (0.41) ALDH1A1KDM4EHSD17B10SMN1; SMN2CYP1A2
SCHEMBL6016397 0.75 CDC7 (0.39) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL5803604 0.72 TACR1 (0.42)
SCHEMBL5802878 0.71 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2LMNANPSR1
Dimethylaminoethanol SCHEMBL6880217 0.70 TACR1 (0.46)
SCHEMBL6016339 0.70 CHRM2 (0.43) ALDH1A1KDM4EHSD17B10SMN1; SMN2MAPT
SCHEMBL10483124 0.70 MAPT (0.45) ALDH1A1KDM4EHSD17B10SMN1; SMN2MAPT
SCHEMBL6016530 0.70 MAPK14 (0.47) ALDH1A1KDM4EHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787539-B2 HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) HOFFMANN-LA ROCHE INC. 2004-09-07 US disclosed
EP-1339698-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-03 EP disclosed
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US disclosed
WO-2002042280-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives TACR1, TACR2, P2RY2 ALDH1A1 1117/4885KDM4E 3664/4885HSD17B10 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.